News
News
Current position:News > News > Insights
AstraZeneca Announces Data from First-in-Human Phase 1 Study of AZD0486, a Novel CD19xCD3 T-Cell Activator, in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
吉满生物
2024-11-08

On 7 Nov, AstraZeneca announced that it will present clinical results for its next-generation T-cell splicer, AZD0486, in relapsed/refractory follicular lymphoma (R/R FL) at this year's American Society of Hematology (ASH) Annual Meeting.

image.png

AZD0486, a novel IgG4 fully human CD19xCD3 bispecific T-cell engager (TCE), is uniquely designed to bind CD3 with low affinity to reduce cytokine release upon T-cell activation, while preserving effective T-cell cytotoxicity against malignant B cells. AZD0486 was active and well tolerated in patients (pts) with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL), including those with R/R diffuse large B-cell lymphoma (DLBCL) (Gaballa, et al. Blood. 2023). Here, we present interim results from the ongoing phase 1, dose-escalation trial of AZD0486 in pts with R/R DLBCL (NCT04594642).  


9595de002183040bf4cd1b1920c6ea1b.png

Drug structure of AZD0486


Conclusion: AZD0486 is active in pts with heavily pretreated DLBCL and responses appear to be target dose–dependent at least up to 15 mg. At target doses evaluated, AZD0486 was well tolerated, with 2SUD mitigating CRS and ICANS events. Dose escalation is ongoing.


Learn more about our CD19/CD3 catalog.

Current position:News > News > Insights
classify
AstraZeneca Announces Data from First-in-Human Phase 1 Study of AZD0486, a Novel CD19xCD3 T-Cell Activator, in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
吉满生物
2024-11-08

On 7 Nov, AstraZeneca announced that it will present clinical results for its next-generation T-cell splicer, AZD0486, in relapsed/refractory follicular lymphoma (R/R FL) at this year's American Society of Hematology (ASH) Annual Meeting.

image.png

AZD0486, a novel IgG4 fully human CD19xCD3 bispecific T-cell engager (TCE), is uniquely designed to bind CD3 with low affinity to reduce cytokine release upon T-cell activation, while preserving effective T-cell cytotoxicity against malignant B cells. AZD0486 was active and well tolerated in patients (pts) with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL), including those with R/R diffuse large B-cell lymphoma (DLBCL) (Gaballa, et al. Blood. 2023). Here, we present interim results from the ongoing phase 1, dose-escalation trial of AZD0486 in pts with R/R DLBCL (NCT04594642).  


9595de002183040bf4cd1b1920c6ea1b.png

Drug structure of AZD0486


Conclusion: AZD0486 is active in pts with heavily pretreated DLBCL and responses appear to be target dose–dependent at least up to 15 mg. At target doses evaluated, AZD0486 was well tolerated, with 2SUD mitigating CRS and ICANS events. Dose escalation is ongoing.


Learn more about our CD19/CD3 catalog.

Tel: 400-627-9288
Message consultation
reset
submit
Service
WhatApp
Phone
Message
Message consultation
reset
submit